• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过[F]FDG-PET/MRI对胆管癌同基因原位模型的表征

Characterization of a Syngeneic Orthotopic Model of Cholangiocarcinoma by [F]FDG-PET/MRI.

作者信息

Zachhuber Lena, Filip Thomas, Mozayani Behrang, Löbsch Mathilde, Scheiner Stefan, Vician Petra, Stanek Johann, Hacker Marcus, Helbich Thomas H, Wanek Thomas, Berger Walter, Kuntner Claudia

机构信息

Preclinical Imaging Lab (PIL), Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria.

Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria.

出版信息

Cancers (Basel). 2024 Jul 19;16(14):2591. doi: 10.3390/cancers16142591.

DOI:10.3390/cancers16142591
PMID:39061229
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11275149/
Abstract

Cholangiocarcinoma (CCA) is a type of primary liver cancer originating from the biliary tract epithelium, characterized by limited treatment options for advanced cases and low survival rates. This study aimed to establish an orthotopic mouse model for CCA and monitor tumor growth using PET/MR imaging. Murine CCA cells were implanted into the liver lobe of male C57BL/6J mice. The imaging groups included contrast-enhanced (CE) MR, CE-MR with static [F]FDG-PET, and dynamic [F]FDG-PET. Tumor volume and FDG uptake were measured weekly over four weeks. Early tumor formation was visible in CE-MR images, with a gradual increase in volume over time. Dynamic FDG-PET revealed an increase in the metabolic glucose rate (MRGlu) over time. Blood analysis showed pathological changes in liver-related parameters. Lung metastases were observed in nearly all animals after four weeks. The study concludes that PET-MR imaging effectively monitors tumor progression in the CCA mouse model, providing insights into CCA development and potential treatment strategies.

摘要

胆管癌（CCA）是一种起源于胆道上皮的原发性肝癌，其特点是晚期病例的治疗选择有限且生存率低。本研究旨在建立一种CCA的原位小鼠模型，并使用PET/MR成像监测肿瘤生长。将小鼠CCA细胞植入雄性C57BL/6J小鼠的肝叶。成像组包括对比增强（CE）MR、静态[F]FDG-PET的CE-MR和动态[F]FDG-PET。在四周内每周测量肿瘤体积和FDG摄取。在CE-MR图像中可见早期肿瘤形成，随着时间的推移体积逐渐增加。动态FDG-PET显示代谢葡萄糖率（MRGlu）随时间增加。血液分析显示肝脏相关参数的病理变化。四周后几乎所有动物都观察到肺转移。该研究得出结论，PET-MR成像可有效监测CCA小鼠模型中的肿瘤进展，为CCA的发展和潜在治疗策略提供见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/274458239f8e/cancers-16-02591-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/130587c8275e/cancers-16-02591-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/3d43dd30ee01/cancers-16-02591-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/462cc200b134/cancers-16-02591-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/786b2bfcb0b1/cancers-16-02591-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/4c1a5d52dde9/cancers-16-02591-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/af0d7c0d470a/cancers-16-02591-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/27784d5a6977/cancers-16-02591-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/274458239f8e/cancers-16-02591-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/130587c8275e/cancers-16-02591-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/3d43dd30ee01/cancers-16-02591-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/462cc200b134/cancers-16-02591-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/786b2bfcb0b1/cancers-16-02591-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/4c1a5d52dde9/cancers-16-02591-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/af0d7c0d470a/cancers-16-02591-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/27784d5a6977/cancers-16-02591-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4d/11275149/274458239f8e/cancers-16-02591-g008.jpg

相似文献

1
Characterization of a Syngeneic Orthotopic Model of Cholangiocarcinoma by [F]FDG-PET/MRI.通过[F]FDG-PET/MRI对胆管癌同基因原位模型的表征
Cancers (Basel). 2024 Jul 19;16(14):2591. doi: 10.3390/cancers16142591.
2
Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.使用 18F-FDG PET 联合双对比增强 CT 和 MRI 监测 MEK 抑制剂 U0126 在 Wt1 敲除 Igf2 转基因小鼠新型 Wilms 肿瘤模型中的治疗效果：无肿瘤生长抑制的早期代谢反应。
Mol Imaging Biol. 2013 Apr;15(2):175-85. doi: 10.1007/s11307-012-0588-5.
3
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
4
68 Ga-FAPI-04 PET/CT for the Evaluation of Cholangiocarcinoma : Comparison With 18 F-FDG PET/CT and Abdominal 68 Ga-FAPI-04 PET/MR.68Ga-FAPI-04 PET/CT 用于胆管癌评估：与 18F-FDG PET/CT 和腹部 68Ga-FAPI-04 PET/MR 的比较
Clin Nucl Med. 2024 May 1;49(5):409-418. doi: 10.1097/RLU.0000000000005112. Epub 2024 Mar 6.
5
Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: A meta-analysis.磁共振成像与18-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在胆管癌患者分期诊断准确性中的比较：一项荟萃分析。
Medicine (Baltimore). 2020 Aug 28;99(35):e20932. doi: 10.1097/MD.0000000000020932.
6
Feasibility and utility of MRI and dynamic F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer.基于器官型子宫内膜癌患者来源的小鼠模型的 MRI 和动态 F-FDG-PET 的可行性和实用性。
J Transl Med. 2021 Sep 26;19(1):406. doi: 10.1186/s12967-021-03086-9.
7
(11)C-Choline and FDG PET/CT Imaging of Primary Cholangiocarcinoma: A Comparative Analysis.(11)原发性胆管癌的C-胆碱与氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描成像：对比分析
Asia Ocean J Nucl Med Biol. 2015 Winter;3(1):18-25.
8
Characterization of an Orthotopic Colorectal Cancer Mouse Model and Its Feasibility for Accurate Quantification in Positron Emission Tomography.一种结直肠原位癌小鼠模型的特征及其在正电子发射断层显像中进行精确定量的可行性。
Mol Imaging Biol. 2017 Oct;19(5):762-771. doi: 10.1007/s11307-017-1051-4.
9
Early Diagnosis of Murine Sepsis-Associated Encephalopathy Using Dynamic PET/CT Imaging and Multiparametric MRI.使用动态 PET/CT 成像和多参数 MRI 对脓毒症相关脑病进行早期诊断。
Mol Imaging Biol. 2022 Dec;24(6):928-939. doi: 10.1007/s11307-022-01743-z. Epub 2022 May 25.
10
Animal PET for thioacetamide-induced rat cholangiocarcinoma: a novel and reliable platform.用于硫代乙酰胺诱导的大鼠胆管癌的动物正电子发射断层显像：一个新颖且可靠的平台
Mol Imaging Biol. 2008 Jul-Aug;10(4):209-16. doi: 10.1007/s11307-008-0141-8. Epub 2008 May 20.

本文引用的文献

1
Circulating Immune Cells Predict Prognosis and Clinical Response to Chemotherapy in Cholangiocarcinoma.循环免疫细胞可预测胆管癌的预后及对化疗的临床反应。
Curr Med Chem. 2025;32(3):595-607. doi: 10.2174/0109298673296618240424095548.
2
Cholangiocarcinoma: Epidemiology and Imaging-Based Review.胆管癌：流行病学和基于成像的综述。
R I Med J (2013). 2024 May 2;107(5):43-48.
3
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management.肝细胞-胆管细胞癌：生物学、诊断与管理
Liver Cancer. 2023 Apr 24;13(1):6-28. doi: 10.1159/000530700. eCollection 2024 Feb.
4
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.
5
Cholangiocarcinoma - novel biological insights and therapeutic strategies.胆管癌——新的生物学见解和治疗策略。
Nat Rev Clin Oncol. 2023 Jul;20(7):470-486. doi: 10.1038/s41571-023-00770-1. Epub 2023 May 15.
6
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.帕博利珠单抗联合吉西他滨和顺铂与单纯吉西他滨和顺铂治疗晚期胆道癌患者的比较（KEYNOTE-966）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.
7
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.胆管癌临床前模型的标准：科学和医学相关性。
Nat Rev Gastroenterol Hepatol. 2023 Jul;20(7):462-480. doi: 10.1038/s41575-022-00739-y. Epub 2023 Feb 8.
8
Diagnosis of Cholangiocarcinoma.胆管癌的诊断
Diagnostics (Basel). 2023 Jan 8;13(2):233. doi: 10.3390/diagnostics13020233.
9
Sex differences: From preclinical pharmacology to clinical pharmacology.性别差异：从临床前药理学到临床药理学
Therapie. 2023 Mar-Apr;78(2):189-194. doi: 10.1016/j.therap.2022.10.005. Epub 2022 Oct 6.
10
Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians.肝内胆管癌治疗进展：临床医生当前及未来治疗前景概述
CA Cancer J Clin. 2023 Mar;73(2):198-222. doi: 10.3322/caac.21759. Epub 2022 Oct 19.